Updates are available Correction dated 2021-12-20

Article History

Received: 19 July 2021

Revised: 25 October 2021

Accepted: 3 November 2021

First Online: 18 November 2021

Change Date: 20 December 2021

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s41416-021-01671-9

Ethics approval and consent to participate

: The study was conducted in accordance with Good Clinical Practice and all applicable regulatory requirements, including the Declaration of Helsinki. Alfred Hospital Ethics Committee (Melbourne, Victoria, Australia), Bellberry Human Research Ethics Committee (Eastwood, South Australia, Australia), and Southern Adelaide Clinical Human Research Ethics Committee (Adelaide, South Australia, Australia) approved the study protocol and informed consent document prior to the initiation of any study-specific procedures. All patients provided written informed consent.

: Not applicable.

: Dr. JDL has no competing interests to declare. Dr. MV reports personal fees from Merck Sharp & Dohme and personal fees from AstraZeneca outside the submitted work. Dr. LM reports other support from BeiGene outside the submitted work. Dr. HG reports personal fees from Merck Serono, Eisai, and Bristol-Myers Squibb outside the submitted work. Dr. GK has nothing to disclose. Dr. KZ, Dr. MZ and Dr. ZT are employees with stock grant or options in BeiGene, Ltd. Dr. MM reports personal fees and non-financial support from AstraZeneca, Bristol-Myers Squibb, and Roche; and personal fees from Merck Sharp & Dohme, Pfizer and Novartis outside the submitted work.